while additional genetic factors or phenotyping approaches may complement pharmacogenetic testing in the future, DPYD genotyping provides an important tool that is available today to identify patients at increased risk of severe adverse effects from FP-based therapies."
No takes yet. Share an insight, caveat, or question.
Hamzic et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: